| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Non-Customized |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Tetracaine HCl Basic Information:
Pharmaceutical Anesthetic Purity HCl Powder CAS 136-47-0 Tetracaine Lidocaine
Lidocaine hydrochloride is swiftly metabolized by the liver, with both metabolites and the unchanged drug excreted through the kidneys. The biotransformation process includes oxidative N-dealkylation, ring hydroxylation, amide linkage cleavage, and conjugation. N-dealkylation, a principal pathway, produces the metabolites monoethylglycinexylidide and glycinexylidide, which have pharmacological and toxicological effects similar to, though less potent than, Lidocaine hydrochloride itself. Approximately 90% of administered Lidocaine hydrochloride is expelled as various metabolites, while less than 10% exits the body unchanged. The primary urinary metabolite is a conjugate of 4-hydroxy-2,6-dimethylaniline.
Lidocaine HCl is an amide local anesthetic.
As the dosage increases, both efficacy and toxicity rise, demonstrating an anti-convulsive effect at sub-toxic plasma concentrations.
Blood concentrations surpassing 5μg/ml can induce convulsions.
){kind=link}